OraSure Technologies, Inc. (OSUR) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
Address
220 East First Street
Bethlehem, PA 18015
United States of America (the)
Phone
610 882 1820
Website
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
501
First IPO Date
November 17, 1986
| Name | Title | Pay | Year Born |
| Carrie Eglinton Manner | President, Chief Executive Officer & Director | 898,040 | 1975 |
| Kenneth J. McGrath | Chief Financial Officer | 577,440 | 1972 |
| Karen Davies | Diagnostics R&D & Chief Technologist | 0 | N/A |
| Amy Steigerwalt | Senior Vice President of Human Resources | 0 | N/A |
| Michele Anthony | Senior Vice President, Chief Accounting Officer, Controller & Assistant Secretary | 0 | 1974 |
| Zachary Wert | Senior Vice President of Global Operations | 0 | N/A |
| Jason Michael Plagman | Vice President of Investor Relations | 0 | N/A |
| Rafal Iwasiow | Sample Management Solutions R&D & Chief Scientist | 0 | N/A |
| David A. Rappaport | Senior Vice President of Corporate Development, Strategy & Integration | 0 | N/A |
| Stefano Taucer | General Counsel & Corporate Secretary | 0 | N/A |
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.